Skip to main content
. 2017 Dec 28;17:895. doi: 10.1186/s12885-017-3897-x

Fig. 1.

Fig. 1

IMPC is associated with poor outcome to adjuvant trastuzumab treatment in HER2-positive breast cancer patients. a Forest plot showing the hazard ratios (HR, squares) and 95% confidence intervals (CI, horizontal lines) of Cox univariate subgroup analysis. b Kaplan–Meier analysis of the probability of DFS of patients who received adjuvant trastuzumab treatment, based on the presence of IMPC. Log rank test was used